PROCEPT BioRobotics Corp.
- PRCT ยท Nasdaq
- Surgical & Medical Instruments & Apparatus
- San Jose, CA
- 888 employees
- CIK 0001588978
Updated from SEC filings through
Top things to know
Executives
- Larry Wood Chief Executive Officer 8-K, 2026-11-04
- Larry L. Wood President, CEO 4, 2026-08-10
- Kevin Waters EVP, CFO 4, 2026-09-10
- Barry L. Templin EVP, Chief Technology Officer 4, 2026-09-10
- Pooja Sharma Chief Strat/Marketing Officer 4, 2026-08-14
-
Alaleh Nouri EVP, CLO, CORP. SEC. 4, 2026-09-10
What leadership is saying
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
PROCEPT BioRobotics Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in San Jose, CA. It trades as PRCT on Nasdaq. Revenue was $308M in the fiscal year ending December 31, 2025, +37.2% from the year before. It reported about 888 employees. Larry Wood is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $308M 10-K, 2026-02-26 | $224M 10-K, 2026-02-26 | $136M 10-K, 2026-02-26 | $75.0M 10-K, 2025-02-27 | $34.5M 10-K, 2024-02-28 |
| Operating income | -$104M 10-K, 2026-02-26 | -$96.6M 10-K, 2026-02-26 | -$109M 10-K, 2026-02-26 | -$80.7M 10-K, 2025-02-27 | -$54.2M 10-K, 2024-02-28 |
| SG&A | $229M 10-K, 2026-02-26 | $171M 10-K, 2026-02-26 | $132M 10-K, 2026-02-26 | $88.8M 10-K, 2025-02-27 | $51.0M 10-K, 2024-02-28 |
| Net income | -$95.6M 10-K, 2026-02-26 | -$91.4M 10-K, 2026-02-26 | -$106M 10-K, 2026-02-26 | -$87.2M 10-K, 2025-02-27 | -$59.9M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Larry Wood | Chief Executive Officer | 8-K, 2026-11-04 |
| Larry L. Wood | President, CEO | 4, 2026-08-10 |
| Kevin Waters Chief Financial Officer at PROCEPT BioRobotics | EVP, CFO | 4, 2026-09-10 |
| Barry L. Templin Chief Technology Officer | EVP, Chief Technology Officer | 4, 2026-09-10 |
| Pooja Sharma | Chief Strat/Marketing Officer | 4, 2026-08-14 |
| Alaleh Nouri EVP, Chief Legal Officer at PROCEPT BioRobotics | EVP, CLO, CORP. SEC. | 4, 2026-09-10 |
| Antal Desai | Board member (per proxy) bio: director | DEF 14A, 2026-04-22 |
| Daniel Puckett | Board member (per proxy) bio: director | DEF 14A, 2026-04-22 |
| Elisabeth Little | Board member (per proxy) bio: director | DEF 14A, 2026-04-22 |
| Frederic Moll, M.D. | Board member (per proxy) bio: director | DEF 14A, 2026-04-22 |
| Mary Garrett | Board member (per proxy) bio: director | DEF 14A, 2026-04-22 |
| Thomas M. Prescott | Board member (per proxy) bio: Chair of the Board | DEF 14A, 2026-04-22 |
What PROCEPT BioRobotics Corp does
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 57.5 million (as of October 29, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $3.2B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 22, 2026) | DEF 14A, April 22, 2026 |
| Auditor | PricewaterhouseCoopers LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 6, 2026 | Pooja Sharma Chief Strat/Marketing Officer | Sale | 4,710 | $93K | Form 4, November 6, 2026 |
| September 9, 2026 | Kevin Waters EVP, CFO | Sale | 373 | $8K | Form 4, September 10, 2026 |
| September 9, 2026 | Alaleh Nouri EVP, CLO, CORP. SEC. | Sale | 297 | $6K | Form 4, September 10, 2026 |
| September 9, 2026 | Barry L. Templin EVP, Chief Technology Officer | Sale | 373 | $8K | Form 4, September 10, 2026 |
| August 7, 2026 | Larry L. Wood President, CEO | Buy | 23,900 | $498K | Form 4, August 10, 2026 |
| June 8, 2026 | Alaleh Nouri EVP, CLO, CORP. SEC. | Sale | 285 | $8K | Form 4, June 10, 2026 |
| June 8, 2026 | Kevin Waters EVP, CFO | Sale | 357 | $10K | Form 4, June 10, 2026 |
| June 8, 2026 | Barry L. Templin EVP, Chief Technology Officer | Sale | 358 | $10K | Form 4, June 10, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-02
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-24
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-08-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-10
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-06
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-26
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-25
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about PROCEPT BioRobotics Corp
- What does PROCEPT BioRobotics Corp do?
- In its own words, from Item 1 of its 10-K: "We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States."
- What is PROCEPT BioRobotics Corp's revenue?
- $308M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is PROCEPT BioRobotics Corp profitable?
- PROCEPT BioRobotics Corp reported net income of -$95.6M for the fiscal year ending December 31, 2025.
- How many employees does PROCEPT BioRobotics Corp have?
- About 888 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of PROCEPT BioRobotics Corp?
- Larry Wood, Chief Executive Officer, as named in a 8-K filed November 4, 2026.
- Who is the CFO of PROCEPT BioRobotics Corp?
- Kevin Waters, EVP, CFO, as named in a 4 filed September 10, 2026.
- Where is PROCEPT BioRobotics Corp headquartered?
- San Jose, CA.
- What is PROCEPT BioRobotics Corp's stock ticker?
- PRCT on Nasdaq.
- What industry is PROCEPT BioRobotics Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is PROCEPT BioRobotics Corp's website?
- procept-biorobotics.com.
- When does PROCEPT BioRobotics Corp report earnings next?
- February 9, 2027. Source: estimate_8k_pattern.
- Is PROCEPT BioRobotics Corp a public company?
- Yes. PROCEPT BioRobotics Corp files with the SEC under CIK 0001588978 and trades as PRCT.
- Who audits PROCEPT BioRobotics Corp?
- PricewaterhouseCoopers LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of PROCEPT BioRobotics Corp are outstanding?
- 57.5 million shares as of October 29, 2026, from its 10-Q filed November 4, 2026.
- What is PROCEPT BioRobotics Corp's public float?
- $3.2B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- When is PROCEPT BioRobotics Corp's annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 22, 2026.
- Have PROCEPT BioRobotics Corp insiders traded stock recently?
- Since August 13, 2025, officers and directors reported 13 open-market sales worth about $717K and 3 purchases worth about $11.8M on Forms 4 and 5. The most recent: Pooja Sharma (Chief Strat/Marketing Officer) sold 4,710 shares on November 6, 2026.